U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

gefitinib response - Efficacy

MedGen UID:
1003295
•Concept ID:
CN322733
•
Sign or Symptom

Professional guidelines

PubMed

Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.
Raoul JL, Moreau-Bachelard C, Gilabert M, Edeline J, Frénel JS
ESMO Open 2023 Feb;8(1):100880. Epub 2023 Feb 8 doi: 10.1016/j.esmoop.2023.100880. PMID: 36764092Free PMC Article
Targeted Drug/Gene/Photodynamic Therapy via a Stimuli-Responsive Dendritic-Polymer-Based Nanococktail for Treatment of EGFR-TKI-Resistant Non-Small-Cell Lung Cancer.
Huang J, Zhuang C, Chen J, Chen X, Li X, Zhang T, Wang B, Feng Q, Zheng X, Gong M, Gong Q, Xiao K, Luo K, Li W
Adv Mater 2022 Jul;34(27):e2201516. Epub 2022 May 31 doi: 10.1002/adma.202201516. PMID: 35481881
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment.
Passaro A, Guerini-Rocco E, Pochesci A, Vacirca D, Spitaleri G, Catania CM, Rappa A, Barberis M, de Marinis F
Pharmacol Res 2017 Mar;117:406-415. Epub 2017 Jan 12 doi: 10.1016/j.phrs.2017.01.003. PMID: 28089942

Recent clinical studies

Etiology

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B
J Clin Oncol 2023 Sep 10;41(26):4208-4217. Epub 2023 Jun 28 doi: 10.1200/JCO.23.00515. PMID: 37379502
Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H, Liu H, Li H, Dou W, Wang J, Zhang J, Liu T, Wu Y, Liu Y, Wang X
Stem Cell Res Ther 2022 Jun 9;13(1):244. doi: 10.1186/s13287-022-02913-0. PMID: 35681225Free PMC Article
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q
J Clin Oncol 2022 Sep 20;40(27):3162-3171. Epub 2022 May 17 doi: 10.1200/JCO.21.02641. PMID: 35580297Free PMC Article
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators
N Engl J Med 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18 doi: 10.1056/NEJMoa1713137. PMID: 29151359
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308

Diagnosis

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study.
Hou X, Li M, Wu G, Feng W, Su J, Jiang H, Jiang G, Chen J, Zhang B, You Z, Liu Q, Chen L
JAMA Netw Open 2023 Feb 1;6(2):e2255050. doi: 10.1001/jamanetworkopen.2022.55050. PMID: 36753281Free PMC Article
Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H, Liu H, Li H, Dou W, Wang J, Zhang J, Liu T, Wu Y, Liu Y, Wang X
Stem Cell Res Ther 2022 Jun 9;13(1):244. doi: 10.1186/s13287-022-02913-0. PMID: 35681225Free PMC Article
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group
J Clin Oncol 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4 doi: 10.1200/JCO.19.01488. PMID: 31682542
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS
Lancet Oncol 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25 doi: 10.1016/S1470-2045(17)30608-3. PMID: 28958502
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group
N Engl J Med 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. PMID: 20573926

Therapy

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B
J Clin Oncol 2023 Sep 10;41(26):4208-4217. Epub 2023 Jun 28 doi: 10.1200/JCO.23.00515. PMID: 37379502
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q
J Clin Oncol 2022 Sep 20;40(27):3162-3171. Epub 2022 May 17 doi: 10.1200/JCO.21.02641. PMID: 35580297Free PMC Article
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group
J Clin Oncol 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4 doi: 10.1200/JCO.19.01488. PMID: 31682542
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators
N Engl J Med 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18 doi: 10.1056/NEJMoa1713137. PMID: 29151359
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308

Prognosis

Colorectal Cancer Organoid-Stroma Biobank Allows Subtype-Specific Assessment of Individualized Therapy Responses.
Farin HF, Mosa MH, Ndreshkjana B, Grebbin BM, Ritter B, Menche C, Kennel KB, Ziegler PK, Szabó L, Bollrath J, Rieder D, Michels BE, Kress A, Bozlar M, Darvishi T, Stier S, Kur IM, Bankov K, Kesselring R, Fichtner-Feigl S, Brüne B, Goetze TO, Al-Batran SE, Brandts CH, Bechstein WO, Wild PJ, Weigert A, Müller S, Knapp S, Trajanoski Z, Greten FR
Cancer Discov 2023 Oct 5;13(10):2192-2211. doi: 10.1158/2159-8290.CD-23-0050. PMID: 37489084Free PMC Article
Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H, Liu H, Li H, Dou W, Wang J, Zhang J, Liu T, Wu Y, Liu Y, Wang X
Stem Cell Res Ther 2022 Jun 9;13(1):244. doi: 10.1186/s13287-022-02913-0. PMID: 35681225Free PMC Article
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group
J Clin Oncol 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4 doi: 10.1200/JCO.19.01488. PMID: 31682542
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators
N Engl J Med 2018 Jan 11;378(2):113-125. Epub 2017 Nov 18 doi: 10.1056/NEJMoa1713137. PMID: 29151359
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS
Lancet Oncol 2017 Nov;18(11):1454-1466. Epub 2017 Sep 25 doi: 10.1016/S1470-2045(17)30608-3. PMID: 28958502

Clinical prediction guides

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JC, Cicin I, Kim DW, Wu YL, Lu S, Lee KH, Pang YK, Zimina A, Fong CH, Poddubskaya E, Sezer A, How SH, Danchaivijitr P, Kim Y, Lim Y, An T, Lee H, Byun HM, Zaric B
J Clin Oncol 2023 Sep 10;41(26):4208-4217. Epub 2023 Jun 28 doi: 10.1200/JCO.23.00515. PMID: 37379502
EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G, Meng R, Chen Y, Yang M, Shen Q, Chu Q, Xia S, Zhang P, Zhang L, Chen Y, Zhang L
Radiother Oncol 2023 Jul;184:109681. Epub 2023 Apr 25 doi: 10.1016/j.radonc.2023.109681. PMID: 37105304
Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H, Liu H, Li H, Dou W, Wang J, Zhang J, Liu T, Wu Y, Liu Y, Wang X
Stem Cell Res Ther 2022 Jun 9;13(1):244. doi: 10.1186/s13287-022-02913-0. PMID: 35681225Free PMC Article
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q
J Clin Oncol 2022 Sep 20;40(27):3162-3171. Epub 2022 May 17 doi: 10.1200/JCO.21.02641. PMID: 35580297Free PMC Article
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group
J Clin Oncol 2020 Jan 10;38(2):115-123. Epub 2019 Nov 4 doi: 10.1200/JCO.19.01488. PMID: 31682542

Recent systematic reviews

Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection - A systematic review.
Brandão M, Durieux V, Auprih M, Fozza A, Dauby N, Cuccia F, Aspeslagh S, Verhaert M, Giaj-Levra N
Lung Cancer 2023 Apr;178:75-86. Epub 2023 Jan 21 doi: 10.1016/j.lungcan.2023.01.010. PMID: 36806897
Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.
Li X, Wang F, Jia H, Lian Z, Ren K, Yuan Z, Wang P, Zhao L
Future Oncol 2022 Sep;18(27):3055-3065. Epub 2022 Aug 10 doi: 10.2217/fon-2022-0491. PMID: 35947522
Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
Yang F, Zhang W, Shang X, Liu N, Ma X, Qin J, Zhang Y, Liu Y, Wang X
Crit Rev Oncol Hematol 2022 Sep;177:103760. Epub 2022 Jul 21 doi: 10.1016/j.critrevonc.2022.103760. PMID: 35870763
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.
Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J
BMJ 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460. PMID: 31591158Free PMC Article
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J
Int J Cancer 2017 Jun 15;140(12):2805-2819. Epub 2017 Mar 27 doi: 10.1002/ijc.30691. PMID: 28295308

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...